Pfizer, BioNTech begin testing of third dose against new COVID-19 variants

Pfizer, BioNTech begin testing of third dose against new COVID-19 variants

Lokmat

Pfizer and its partner BioNTech on Thursday said that they have begun to test how well the third dose of their authorised vaccine stacks up against new coronavirus variants.

Pfizer and its partner BioNTech on Thursday said that they have begun to test how well the third dose of their authorised vaccine stacks up against new coronavirus variants.

The study will evaluate up to 144 Phase 1 participants in two age cohorts, 18-55 and 65-85 years of age. The study will include trial participants who received the two doses in the Phase 1 study 6 to 12 months ago in order to assess the boostability of BNT162b2 (the vaccine), the compes said.

Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

140529478

Cases

119353154

Recovered

3006648

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019